Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma

SIMPLE SUMMARY: Cetuximab remains a viable treatment for patients with advanced cutaneous squamous cell carcinoma who fail or are ineligible for immunotherapy. When used immediately following the progression of anti-PD1 therapy, cetuximab demonstrated particularly rapid and durable responses in our...

Descripción completa

Detalles Bibliográficos
Autores principales: Marin-Acevedo, Julian A., Withycombe, Bethany M., Kim, Youngchul, Brohl, Andrew S., Eroglu, Zeynep, Markowitz, Joseph, Tarhini, Ahmad A., Tsai, Kenneth Y., Khushalani, Nikhil I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295991/
https://www.ncbi.nlm.nih.gov/pubmed/37370790
http://dx.doi.org/10.3390/cancers15123180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295991/
https://www.ncbi.nlm.nih.gov/pubmed/37370790
http://dx.doi.org/10.3390/cancers15123180

Ejemplares similares